13 active not recruiting, 7 completed, 6 recruiting, 6 unknown. 40 Phase 3, 7 Phase 2.
Follow intensity-modulated radiotherapy: new trials by email Literature Review of intensity-modulated radiotherapy trials Research Report on intensity-modulated radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-10-27 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-03-05 | 2026-03-16 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 418 | 2026-01-15 | 2026-01-28 |
| Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma Adebrelimab (PD-L1 inhibitor), Cisplatin (100mg/m2), Intensity-modulated radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 516 | 2025-12-01 | 2025-11-20 |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Biospecimen Collection, Brachytherapy, Carboplatin - Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2025-11-05 | 2026-10-28 |
| QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. QL1706, Gemcitabine, Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Recruiting | Sun Yat-Sen University Cancer Center | 580 | 2025-05-04 | 2025-05-22 |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma | Phase 3 | Suspended | National Cancer Institute (NCI) | 420 | 2025-02-18 | 2026-10-20 |
| Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 3 | Active not recruiting | Sun Yat-sen University | 490 | 2023-08-01 | 2025-01-23 |
| Optimization of Cervical Nodal CTV for Early and Medium Stage NPC intensity-modulated radiotherapy (IMRT) with reduced-volume, Chemotherapy - Nasopharyngeal Carcinoma | Phase 3 | Active not recruiting | Yi Junlin | 414 | 2022-09-01 | 2026-05-28 |
| PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2) - Nasopharyngeal Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 532 | 2021-08-01 | 2025-07-16 |
| Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma Temozolomide - Glioblastoma | Phase 3 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 80 | 2020-11-01 | 2021-04-02 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-08-19 |
| Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma Carboplatin, Cisplatin, Decortication - Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma | Phase 3 | Terminated | NRG Oncology | 16 | 2020-01-29 | 2026-07-13 |
| De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 384 | 2019-10-09 | 2026-07-02 |
| Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 636 | 2019-08-16 | 2026-10-26 |
| Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection - Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 544 | 2019-07-26 | 2026-08-27 |
Showing 20 of 40. Sign in to see all of them.
Nasopharyngeal Carcinoma (8) · Nasopharyngeal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Oropharyngeal Neoplasms (3) · Glioblastoma (2) · Uterine Cervical Neoplasms (2) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Cognitive Dysfunction (1) · Epstein-Barr Virus Infections (1) · Fatigue (1) · Gliosarcoma (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1)
National Cancer Institute (NCI) (11) · Sun Yat-sen University (9) · NRG Oncology (8) · Chinese Academy of Medical Sciences (1) · ECOG-ACRIN Cancer Research Group (1) · First Affiliated Hospital of Guangxi Medical University (1) · GOG Foundation (1) · Gynecologic Oncology Group (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Radiation Therapy Oncology Group (1) · SWOG Cancer Research Network (1) · Sun Yat-Sen University Cancer Center (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Yi Junlin (1)
United States (25) · Canada (13) · China (12) · Hong Kong (3) · Japan (3) · Puerto Rico (3) · Australia (2) · India (2) · Israel (2) · South Korea (2) · Belgium (1) · Ireland (1) · Saudi Arabia (1) · Singapore (1) · Switzerland (1)
Jun Ma, M.D. (4) · Fang-Yun Xie, M.D. (2) · Loren K Mell (2) · Andreas Rimner, MD (1) · Andy M. Trotti, MD (1) · Charles A Leath (1) · David A Liebner (1) · Jeremy P Harris (1) · Jun Ma, MD (1) · Junlin Yi (1) · Junlin Yi, professor (1) · Jyoti S Mayadev (1) · Kristin A Higgins (1) · Marcus E Randall (1) · Mark Gilbert (1)
PMID 28837405, PMID 29584545, PMID 31150573, PMID 24552317, PMID 25057165, PMID 27084653, PMID 29868473, PMID 30213452, PMID 30449625, PMID 30995174, PMID 31681600, PMID 31912685, PMID 32058845, PMID 33370024, PMID 33492986, PMID 34632876, PMID 35986837, PMID 36006678, PMID 36223780, PMID 36401615, PMID 37222189, PMID 37537541, PMID 37598723, PMID 38131628, PMID 38421243, PMID 38824941, PMID 39438442, PMID 39551064, PMID 39938471, PMID 40651471, PMID 40789106, PMID 40839372, PMID 40947016, PMID 41005671, PMID 41063518, PMID 41137728, PMID 41290309, PMID 41343184, PMID 41391462, PMID 41529214, PMID 41791006, PMID 42456089, PMID 42532339, PMID 42593775, PMID 42658511
U10CA180868 (16), U10CA021661 (4), U10CA180820 (3), UG1CA189867 (2), R03CA188162 (1), R56DE025248 (1), U10CA027469 (1), U10CA180822 (1), U10CA180830 (1), U10CA180888 (1), U19CA021239 (1)